JP2013518086A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518086A5 JP2013518086A5 JP2012550464A JP2012550464A JP2013518086A5 JP 2013518086 A5 JP2013518086 A5 JP 2013518086A5 JP 2012550464 A JP2012550464 A JP 2012550464A JP 2012550464 A JP2012550464 A JP 2012550464A JP 2013518086 A5 JP2013518086 A5 JP 2013518086A5
- Authority
- JP
- Japan
- Prior art keywords
- radioimmunoconjugate
- monoclonal antibody
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940051022 radioimmunoconjugate Drugs 0.000 claims 9
- 238000000034 method Methods 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000048426 human CD37 Human genes 0.000 claims 1
- 238000002625 monoclonal antibody therapy Methods 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29952410P | 2010-01-29 | 2010-01-29 | |
| NO20100143 | 2010-01-29 | ||
| US61/299,524 | 2010-01-29 | ||
| NO20100143A NO331080B1 (no) | 2010-01-29 | 2010-01-29 | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| PCT/EP2011/051231 WO2011092295A2 (en) | 2010-01-29 | 2011-01-28 | Novel radioimmunoconjugates and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014225005A Division JP5855209B2 (ja) | 2010-01-29 | 2014-11-05 | 放射免疫コンジュゲートおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518086A JP2013518086A (ja) | 2013-05-20 |
| JP2013518086A5 true JP2013518086A5 (enExample) | 2014-04-03 |
| JP5646652B2 JP5646652B2 (ja) | 2014-12-24 |
Family
ID=44319900
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012550464A Expired - Fee Related JP5646652B2 (ja) | 2010-01-29 | 2011-01-28 | 放射免疫コンジュゲートおよびその使用 |
| JP2014225005A Active JP5855209B2 (ja) | 2010-01-29 | 2014-11-05 | 放射免疫コンジュゲートおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014225005A Active JP5855209B2 (ja) | 2010-01-29 | 2014-11-05 | 放射免疫コンジュゲートおよびその使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8628749B2 (enExample) |
| EP (2) | EP2705857B1 (enExample) |
| JP (2) | JP5646652B2 (enExample) |
| KR (2) | KR101893720B1 (enExample) |
| CN (2) | CN104338154B (enExample) |
| AU (1) | AU2011209441B2 (enExample) |
| BR (1) | BR112012018843B8 (enExample) |
| CA (1) | CA2786655C (enExample) |
| DK (2) | DK2705857T3 (enExample) |
| ES (2) | ES2469140T3 (enExample) |
| HR (1) | HRP20140538T1 (enExample) |
| IL (2) | IL221091A (enExample) |
| MX (2) | MX342539B (enExample) |
| NO (1) | NO331080B1 (enExample) |
| NZ (1) | NZ601055A (enExample) |
| PH (2) | PH12012501516A1 (enExample) |
| PL (1) | PL2528627T3 (enExample) |
| PT (1) | PT2528627E (enExample) |
| RS (1) | RS53346B (enExample) |
| RU (2) | RU2560587C9 (enExample) |
| SG (1) | SG182685A1 (enExample) |
| SI (1) | SI2528627T1 (enExample) |
| UA (1) | UA108631C2 (enExample) |
| WO (1) | WO2011092295A2 (enExample) |
| ZA (1) | ZA201205007B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1203372A1 (en) * | 2011-12-13 | 2015-10-30 | Nordic Nanovector Asa | Chimeric therapeutic anti - cd37 antibodie hh1 |
| US20150093397A1 (en) * | 2012-03-30 | 2015-04-02 | Immunogen, Inc. | Methods for Increasing Efficacy of CD37-Based Therapy |
| CN103933575B (zh) * | 2013-01-23 | 2017-09-29 | 上海新理念生物医药科技有限公司 | 一种三齿型连接子及其应用 |
| EP3332813B1 (en) * | 2013-06-07 | 2019-05-29 | Nordic Nanovector ASA | Combination therapy comprising anti-cd20 antibody and the radiolabeled hh1 monoclonal antibody |
| AU2014296219A1 (en) | 2013-08-01 | 2016-02-25 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to CD37 proteins |
| BR112017020689A2 (en) * | 2015-04-07 | 2018-06-26 | Memorial Sloan-Kettering Cancer Center | nanoparticulate immunoconjugates |
| GB201600328D0 (en) * | 2016-01-08 | 2016-02-24 | Univ Oslo Hf | Anti-CD37 chimeric antigen receptors and immune cells expressing them |
| JP2019529433A (ja) * | 2016-09-16 | 2019-10-17 | ノルディック ナノベクター アルメン アクスイェ セルスカプ | リロトマブおよび１７７Ｌｕ‐リロトマブ・サテトラキセタンを用いた非ホジキンリンパ腫の治療方法 |
| KR102406510B1 (ko) | 2017-07-03 | 2022-06-10 | 현대자동차주식회사 | 연료전지 시스템용 수소 공급 방법 |
| CN109550061A (zh) * | 2017-09-26 | 2019-04-02 | 南京江原安迪科正电子研究发展有限公司 | 一种用于放射性核素标记抗体的试剂盒及应用 |
| US20210106703A1 (en) * | 2017-11-22 | 2021-04-15 | Nordic Nanovector Asa | Radioimmunoconjugates in combination with other drugs as treatment against nhl |
| CA3137568A1 (en) * | 2019-04-25 | 2020-10-29 | Actinium Pharmaceuticals, Inc. | Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases |
| CN117241832A (zh) * | 2021-03-19 | 2023-12-15 | 海德堡医药研究有限责任公司 | B淋巴细胞特异性的鹅膏毒素抗体缀合物 |
| WO2023057595A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 rew |
| US20250333531A1 (en) | 2021-10-06 | 2025-10-30 | Nordic Nanovector Asa | Humanized hh1 |
| CN114081969A (zh) * | 2021-11-23 | 2022-02-25 | 成都纽瑞特医疗科技股份有限公司 | 标记的小分子抗体、及其标记方法和应用 |
| CN117285631A (zh) * | 2023-11-24 | 2023-12-26 | 原子高科股份有限公司 | 用于放射性免疫治疗的Lu-177标记MUC1抗体 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| MXPA02010507A (es) * | 2000-04-25 | 2003-05-14 | Idec Pharma Corp | Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central. |
| RU2005122033A (ru) * | 2002-12-13 | 2006-01-27 | Митра Медикал Текнолоджи Аб (Se) | Направленные противолимфомные средства с эффекторной и аффиновой функциями, связанные трехфункциональным реагентом |
| US7534427B2 (en) * | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| EP1587550B1 (en) * | 2003-01-31 | 2011-07-27 | Immunomedics, Inc. | Methods and compositions for administering therapeutic and diagnostic agents |
| WO2005084179A2 (en) * | 2003-12-01 | 2005-09-15 | Immunomedics, Inc. | Improved method for preparing conjugates of proteins and chelating agents |
| HUE026303T2 (hu) * | 2005-07-25 | 2016-06-28 | Emergent Product Dev Seattle | B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával |
| PE20090499A1 (es) | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
-
2010
- 2010-01-29 NO NO20100143A patent/NO331080B1/no not_active IP Right Cessation
-
2011
- 2011-01-28 CN CN201410353070.5A patent/CN104338154B/zh active Active
- 2011-01-28 PL PL11700972T patent/PL2528627T3/pl unknown
- 2011-01-28 CN CN201180007272.9A patent/CN102762230B/zh not_active Expired - Fee Related
- 2011-01-28 CA CA2786655A patent/CA2786655C/en active Active
- 2011-01-28 JP JP2012550464A patent/JP5646652B2/ja not_active Expired - Fee Related
- 2011-01-28 NZ NZ601055A patent/NZ601055A/en not_active IP Right Cessation
- 2011-01-28 PH PH1/2012/501516A patent/PH12012501516A1/en unknown
- 2011-01-28 BR BR112012018843A patent/BR112012018843B8/pt not_active IP Right Cessation
- 2011-01-28 ES ES11700972.0T patent/ES2469140T3/es active Active
- 2011-01-28 UA UAA201208485A patent/UA108631C2/ru unknown
- 2011-01-28 DK DK13195682.3T patent/DK2705857T3/en active
- 2011-01-28 EP EP13195682.3A patent/EP2705857B1/en active Active
- 2011-01-28 MX MX2015000391A patent/MX342539B/es unknown
- 2011-01-28 KR KR1020177018914A patent/KR101893720B1/ko not_active Expired - Fee Related
- 2011-01-28 RU RU2012135430/10A patent/RU2560587C9/ru active
- 2011-01-28 RS RS20140300A patent/RS53346B/sr unknown
- 2011-01-28 PT PT117009720T patent/PT2528627E/pt unknown
- 2011-01-28 RU RU2015127407A patent/RU2664475C1/ru active
- 2011-01-28 KR KR1020127020917A patent/KR101758409B1/ko not_active Expired - Fee Related
- 2011-01-28 SI SI201130157T patent/SI2528627T1/sl unknown
- 2011-01-28 HR HRP20140538AT patent/HRP20140538T1/hr unknown
- 2011-01-28 WO PCT/EP2011/051231 patent/WO2011092295A2/en not_active Ceased
- 2011-01-28 EP EP11700972.0A patent/EP2528627B1/en active Active
- 2011-01-28 SG SG2012054607A patent/SG182685A1/en unknown
- 2011-01-28 ES ES13195682.3T patent/ES2592402T3/es active Active
- 2011-01-28 AU AU2011209441A patent/AU2011209441B2/en not_active Ceased
- 2011-01-28 DK DK11700972.0T patent/DK2528627T3/da active
- 2011-01-28 MX MX2012008695A patent/MX2012008695A/es active IP Right Grant
- 2011-01-28 US US13/522,678 patent/US8628749B2/en active Active
-
2012
- 2012-07-04 ZA ZA2012/05007A patent/ZA201205007B/en unknown
- 2012-07-24 IL IL221091A patent/IL221091A/en active IP Right Grant
-
2013
- 2013-12-09 US US14/100,756 patent/US9358309B2/en active Active
-
2014
- 2014-11-05 JP JP2014225005A patent/JP5855209B2/ja active Active
-
2015
- 2015-03-02 IL IL237507A patent/IL237507A0/en active IP Right Grant
-
2017
- 2017-06-05 PH PH12017501038A patent/PH12017501038B1/en unknown